Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 16, 2005New England Journal of Medicine

COX-2 Inhibitors — Lessons in Drug Safety

View Full Paper
Ask AI
Bookmark
Share

Authors

Bruce M. PsatyBruce M. PsatyGeneral / Preventive / LipidsCurt D. FurbergCurt D. FurbergLinköping University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Psaty et al. (2005) studied this question.

synapsesocial.com/papers/6a5d535cd50e1fe7bb0397d8https://doi.org/10.1056/nejme058042
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial2005 · 2,527 citations
  2. 2Surrogate End Points, Health Outcomes, and the Drug-Approval Process for the Treatment of Risk Factors for Cardiovascular Disease1999 · 187 citations
  3. 3Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis2000 · 4,047 citations
  4. 4Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-21999 · 1,314 citations
  5. 5Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention2005 · 2,056 citations